研究概要
本研究表明,TIL-B在NPC的抗肿瘤免疫中发挥重要的调节作用,并提示其治疗潜力,为开发基于B细胞或靶向TLS的免疫治疗策略提供了依据。
中文摘要
晚期鼻咽癌(NPC)常因远处转移而预后不良,但肿瘤浸润B细胞(TIL-B)的分布特征及抗转移机制尚不清楚。本研究通过单细胞RNA测序结合多重免疫荧光发现,B细胞在非转移性NPC中高度富集并形成完整的三级淋巴结构(TLS),而转移性NPC中TLS缺失。体外和体内功能实验表明,TIL-B及其条件培养基显著抑制NPC细胞增殖、迁移和上皮-间质转化(EMT),同时诱导凋亡;在人源化小鼠模型中,TIL-B抑制皮下肿瘤生长和肺转移,而B细胞清除则加速肿瘤进展。机制上,TIL-B分泌IL-12、IFN-、TNF-和CXCL13。其中,IL-12上调E-cadherin并下调N-cadherin和Vimentin,从而阻断EMT并抑制血管生成拟态(VM);CXCL13可能促进TLS形成并增强局部免疫应答。通过“IL-12-EMT/VM抑制”和“CXCL13-TLS构建”的双重途径,TIL-B协同抑制肿瘤侵袭和转移,构建多维免疫防御系统。本研究表明TIL-B在NPC抗肿瘤免疫中发挥重要调控作用,并提示其治疗潜力,为开发基于B细胞或靶向TLS的免疫治疗策略提供了依据。
展开英文摘要原文
Nasopharyngeal carcinoma (NPC) in advanced stages often has a poor prognosis due to distant metastasis, yet the distribution characteristics and anti-metastatic mechanisms of tumor-infiltrating B cells (TIL-B) remain unclear. In this study, single-cell RNA sequencing combined with multiplex immunofluorescence revealed that B cells were highly enriched in non-metastatic NPC and formed complete tertiary lymphoid structures (TLS), whereas TLS was absent in metastatic NPC. Functional assays in vitro and in vivo showed that TIL-B and their conditioned medium significantly inhibited NPC cell proliferation, migration, and epithelial-mesenchymal transition (EMT), while inducing apoptosis; in humanized mouse models, TIL-B suppressed subcutaneous tumor growth and lung metastasis, whereas B cell depletion accelerated tumor progression. Mechanistically, TIL-B secreted IL-12, IFN- , TNF- , and CXCL13. Among them, IL-12 upregulated E-cadherin and downregulated N-cadherin and Vimentin, thereby blocking EMT and inhibiting vasculogenic mimicry (VM); CXCL13 may promote TLS formation and enhance local immune responses. Through the dual pathways of " IL-12-EMT/VM inhibition" and "CXCL13-TLS construction," TIL-B cooperatively restrains tumor invasion and metastasis, building a multidimensional immune defense system. This study demonstrates that TIL-B play an important regulatory role in anti-tumor immunity in NPC and suggests their therapeutic potential, providing a rationale for the development of B cell-based or TLS-targeted immunotherapeutic strategies.
论文信息
- 作者
- Cai J、Tan X、Liu X、Feng J、Deng X、Zhao L
- 第一作者单位
- Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.China
- 通讯作者单位
- Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China. 508156@csu.edu.cn.China
- 期刊
- Cell death & disease2026 Jun 2